关于造血干细胞移植受者感染新型冠状病毒肺炎患者的综述。
A review on recipients of hematopoietic stem cell transplantation patients with COVID-19 infection.
作者信息
Sahu Kamal Kant, Siddiqui Ahmad Daniyal
机构信息
Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA 01608, USA.
Hemato-Oncology Division, Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA, USA.
出版信息
Ther Adv Infect Dis. 2021 May 5;8:20499361211013252. doi: 10.1177/20499361211013252. eCollection 2021 Jan-Dec.
For the last few months, various geographical regions and health sectors have been facing challenges posed by the current COVID-19 pandemic. COVID-19 has led to significant disruption in the normal functioning of potentially life-saving therapies of hematopoietic cell transplant and chimeric antigen receptor therapy. As transplant physicians are gaining more information and experience regarding the undertaking of these complex procedures during the ongoing COVID-19 pandemic, we believe it is important to discuss the challenges faced, prognostic risk factors, and outcomes of COVID-19 in post-hematopoietic stem cell transplantation patients based on the available real-world data.
在过去几个月里，各个地理区域和卫生部门都面临着当前新冠疫情带来的挑战。新冠疫情已严重扰乱了造血细胞移植和嵌合抗原受体疗法等可能挽救生命的治疗方法的正常运作。随着移植医生在持续的新冠疫情期间获得了更多关于开展这些复杂程序的信息和经验，我们认为，根据现有的真实世界数据，讨论造血干细胞移植后患者感染新冠病毒面临的挑战、预后风险因素及结果很重要。
Zotero 插件